Nestle F,Kaplan D H. Barker Psoriasis[J].N Engl J Med, 2009,361:496-509.
[1]
Nestle F,Kaplan D H. Barker Psoriasis[J].N Engl J Med, 2009,361:496-509.
[2]
Sugiyama H, McCormick T S, Cooper K D, et al. Alefacept in the treatment of psoriasis[J]. Clin Dermatol,2008,26:50-58.
[3]
Pietrzak A T, Zalewska A, Chodorowska G,et al. Cytokines and anticytokines in psoriasiss[J]. Clin Chim Acta,2008,394: 7-21.
[4]
Zaba L C, Cardinale I, Gilleaudeau P,et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responsess[J]. J Exp Med,2013,204: 3183-3194.
[5]
Nograles K E, Krueger J G. Anti-cytokine therapies for psoriasiss[J]. Experimental Cell Res,2011,317(9):1293-1300.
[2]
Sugiyama H, McCormick T S, Cooper K D, et al. Alefacept in the treatment of psoriasis[J]. Clin Dermatol,2008,26:50-58.
[6]
Reich K, Nestle F, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial[J]. Lancet,2005,366(9494):1367-1374.
[7]
Smolen J S, Emery P.Infliximab: 12 years of experiences[J].Arthritis Res Ther,2014,13(Suppl 1): S2.
[3]
Pietrzak A T, Zalewska A, Chodorowska G,et al. Cytokines and anticytokines in psoriasiss[J]. Clin Chim Acta,2008,394: 7-21.
[8]
Menter A, Tyring S K, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trials[J]. J Am Acad Dermatol,2008,58(1):106-115.
[4]
Zaba L C, Cardinale I, Gilleaudeau P,et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responsess[J]. J Exp Med,2013,204: 3183-3194.
[9]
Reich K, Burden A D, Eaton J N,et al. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trialss[J]. Br J Dermatol, 2012,166(1):179-188.
[5]
Nograles K E, Krueger J G. Anti-cytokine therapies for psoriasiss[J]. Experimental Cell Res,2011,317(9):1293-1300.
[10]
Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor α, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled studys[J]. Arthritis Rheum, 2009,60:976-986.
[6]
Reich K, Nestle F, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial[J]. Lancet,2005,366(9494):1367-1374.
[11]
Kavanaugh A, Vander H D, McInnes I B, et al.Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial[J]. Arthritis Rheum,2012,64(8):2504-2517.
[12]
Bonafede M, Johnson B H, Fox K M.Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world settings[J].J Dermatol Treat,2013,24(5): 369-373.
[7]
Smolen J S, Emery P.Infliximab: 12 years of experiences[J].Arthritis Res Ther,2014,13(Suppl 1): S2.
[13]
Ivanov I I, Zhou L, Littman D R. Transcriptional regulation of Th17 cell differentiations[J]. Seminars in Immunology, 2007,19(6):409-417.
[8]
Menter A, Tyring S K, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trials[J]. J Am Acad Dermatol,2008,58(1):106-115.
[9]
Reich K, Burden A D, Eaton J N,et al. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trialss[J]. Br J Dermatol, 2012,166(1):179-188.
[14]
Kimball A B, Gordon K B, Langely R G, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody in the treatment of moderate to severe chronic plaque psoriasis[J]. Arch Dermatol,2013,144:200-207.
[15]
Papp K, Leonardi C, Menter A,et al.Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment[J].J Am Acad Dermatol,2014,71(6):1183-1190.
[10]
Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor α, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled studys[J]. Arthritis Rheum, 2009,60:976-986.
[16]
Langley R G, Elewski B E, Lebwohl M,et al.Secukinumab in plaque psoriasis--results of two phase 3 trials[J].N Engl J Med, 2014,371(4):326-338.
[11]
Kavanaugh A, Vander H D, McInnes I B, et al.Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial[J]. Arthritis Rheum,2012,64(8):2504-2517.
[17]
Ren V, Dao H.Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis[J].Clini Cosme Investigat Dermatol, 2013,6:75-80.
[12]
Bonafede M, Johnson B H, Fox K M.Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world settings[J].J Dermatol Treat,2013,24(5): 369-373.
[18]
Schafer P H, Parton A, Gandhi A K, et al. Apremilast, a cAMP phosphodiesterase-4 inhibiter, demonstrates antiinflammatory activity in vitro and in a model of psoriasis[J]. British Jonrral of Pharmacology, 2010,159(4):842-855.
[13]
Ivanov I I, Zhou L, Littman D R. Transcriptional regulation of Th17 cell differentiations[J]. Seminars in Immunology, 2007,19(6):409-417.
[19]
Palfreeman A C, McNamee K E, McCann F E.New developments in the management of psoriasis and psoriatic arthritis: focus on apremilast[J].Drug Des Devel Ther,2013,7:201-210.
[14]
Kimball A B, Gordon K B, Langely R G, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody in the treatment of moderate to severe chronic plaque psoriasis[J]. Arch Dermatol,2013,144:200-207.
[20]
Matz M, Naik M, Mashreghi M F, et al. Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation[J]. Expert Opin Drug Meta Toxico,2011,7(1):103-113.
[15]
Papp K, Leonardi C, Menter A,et al.Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment[J].J Am Acad Dermatol,2014,71(6):1183-1190.
[21]
He X, Koenen H J, Smeets R L, et al.Targeting PKC in human T cells using sotrastaurin (AEB071) preserves regulatory T cells and prevents IL-17 production[J]. Invest Dermatol,2014,134(4):975-983.
[22]
Westra J, Doornbosvan B, Deboer P,et al. Strong inhibition of TNF-alpha production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor[J].Arthritis Research & Therapy, 2004,6(4):R384-R392.
[23]
Ortiz I K, Alsina M M, Munoz-Santos C. Tofacitinib and other kinase inhibitors in the treatment of psoriasis[J].Actas Dermo-Sifiliograficas,2013,104(4):304-310.
[24]
Raychaudhuri S P, Sanyal M, Weltman H, et al.K252a, a high-affinity nerve growth factor receptor blocker, improves psoriasis: an in vivo study using the severe combined immunodeficient mouse-human skin model[J]. J Invest Dermatol,2004,122(3):812-819.
[25]
Wada Y, Cardinale I, Khatcherian A, et al. Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis[J].PLoS ONE,2012,7(4):e35069.
[16]
Langley R G, Elewski B E, Lebwohl M,et al.Secukinumab in plaque psoriasis--results of two phase 3 trials[J].N Engl J Med, 2014,371(4):326-338.
[17]
Ren V, Dao H.Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis[J].Clini Cosme Investigat Dermatol, 2013,6:75-80.
[18]
Schafer P H, Parton A, Gandhi A K, et al. Apremilast, a cAMP phosphodiesterase-4 inhibiter, demonstrates antiinflammatory activity in vitro and in a model of psoriasis[J]. British Jonrral of Pharmacology, 2010,159(4):842-855.
[19]
Palfreeman A C, McNamee K E, McCann F E.New developments in the management of psoriasis and psoriatic arthritis: focus on apremilast[J].Drug Des Devel Ther,2013,7:201-210.
[20]
Matz M, Naik M, Mashreghi M F, et al. Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation[J]. Expert Opin Drug Meta Toxico,2011,7(1):103-113.
[21]
He X, Koenen H J, Smeets R L, et al.Targeting PKC in human T cells using sotrastaurin (AEB071) preserves regulatory T cells and prevents IL-17 production[J]. Invest Dermatol,2014,134(4):975-983.
[22]
Westra J, Doornbosvan B, Deboer P,et al. Strong inhibition of TNF-alpha production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor[J].Arthritis Research & Therapy, 2004,6(4):R384-R392.
[23]
Ortiz I K, Alsina M M, Munoz-Santos C. Tofacitinib and other kinase inhibitors in the treatment of psoriasis[J].Actas Dermo-Sifiliograficas,2013,104(4):304-310.
[24]
Raychaudhuri S P, Sanyal M, Weltman H, et al.K252a, a high-affinity nerve growth factor receptor blocker, improves psoriasis: an in vivo study using the severe combined immunodeficient mouse-human skin model[J]. J Invest Dermatol,2004,122(3):812-819.
[25]
Wada Y, Cardinale I, Khatcherian A, et al. Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis[J].PLoS ONE,2012,7(4):e35069.
2015, Vol. 26 
